Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2026
Pendopharm announces the approval of Yorvipath (palopegteriparatide injection) for the treatment of chronic hypoparathyroidism in adults
6 February 2026 - Pendopharm announced today that Health Canada has granted market authorisation for Yorvipath (palopegteriparatide injection), a parathyroid ...
Posted by Michael Wonder on 07 Feb 2026
Kisqali receives positive draft recommendation from Canada's Drug Agency for all eligible early breast cancer patients at high risk of recurrence
6 February 2026 - The draft recommendation for Kisqali (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone ...
Posted by Michael Wonder on 06 Feb 2026
Teva Canada announces approval of expanded indication of Ajovy (fremanezumab solution for subcutaneous injection), the first anti-CGRP preventive treatment for paediatric episodic migraine
4 February 2026 - Teva Canada announced today that Health Canada has approved an expanded indication for Ajovy (fremanezumab solution for ...
Posted by Michael Wonder on 06 Feb 2026
Merck announces Health Canada approval of Enflonsia for the prevention of RSV in newborns and infants
5 February 2026 - Approval is based on the CLEVER and SMART clinical trial results. ...
Posted by Michael Wonder on 04 Feb 2026
Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft versus host disease
3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients ...
Posted by Michael Wonder on 04 Feb 2026
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer
3 February 2026 - GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for ...
Posted by Michael Wonder on 03 Feb 2026
Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, now available in Canada for adult patients with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia
27 January 2026 - The approval of Jaypirca marks Lilly Canada's first haematology launch in Canada. ...
Posted by Michael Wonder on 03 Feb 2026
Health Canada grants authorization for Bayer’s Hyrnuo (sevabertinib) for previously treated patients with locally advanced or metastatic HER2-mutant non-small cell lung cancer
2 February 2026 - Bayer is pleased to announce that Health Canada has authorized Hyrnuo (sevabertinib), oral tablets, for the treatment ...
Posted by Michael Wonder on 30 Jan 2026
Canadians wait too long for access to innovative drugs, cautions the MEI
29 January 2026 - Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death ...
Posted by Michael Wonder on 30 Jan 2026
Celltrion secures Canadian approval for Omlyclo 300 mg PFS and auto-injector formulations
29 January 2026 - Celltrion said Thursday that it has received additional approval from Health Canada for its chronic idiopathic ...
Posted by Michael Wonder on 30 Jan 2026
Government of Canada announces the new Chairperson of the Patented Medicine Prices Review Board
29 January 2026 - Today, the Honourable Marjorie Michel, Minister of Health, announced the designation of a new Chairperson for ...
Posted by Michael Wonder on 29 Jan 2026
Cipher Pharmaceuticals announces Health Canada's acceptance for review of new drug submission for Natroba (spinosad)
28 January 2026 - Cipher Pharmaceuticals today announced that Health Canada has accepted for review Cipher's new drug submission for ...
Posted by Michael Wonder on 27 Jan 2026
Health Canada authorises Gazyva (obinutuzumab) for adults with active lupus nephritis
26 January 2026 - Roche Canada is pleased to announce that on 22 January 2026, Health Canada has approved Gazyva ...
Posted by Michael Wonder on 26 Jan 2026
Patient organisations welcome approval of six life-extending cancer treatments through Ontario's FAST Program, urge national expansion
23 January 2026 - Leading patient organisations are welcoming Ontario's announcement that six cancer drugs are now being fast-tracked for ...
Posted by Michael Wonder on 26 Jan 2026
AstraZeneca's Tagrisso and Calquence among first oncology treatments granted accelerated access through Ontario's FAST Program
23 January 2026 - AstraZeneca Canada is pleased to announce that Tagrisso (osimertinib) and Calquence (acalabrutinib tablets) are now publicly funded ...